1
|
Cluse F, Bernard E, Strubi-Vuillaume I, Devos D, Mouzat K, Lumbroso S, Froment Tilikete C, Thobois S, Pegat A. Amyotrophic lateral sclerosis associated with a pathological expansion in the ATXN7 gene. Amyotroph Lateral Scler Frontotemporal Degener 2021; 23:470-472. [PMID: 34870541 DOI: 10.1080/21678421.2021.1998537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Spinocerebellar ataxia type 7 (SCA7) is an autosomal dominant hereditary neurodegenerative disease caused by the expansion of a CAG-repeat in the ataxin-7 (ATXN7) gene, usually characterized by progressive cerebellar ataxia and retinal dystrophy. We report the case of a 45-year-old woman presenting with a rapid-onset amyotrophic lateral sclerosis (ALS) phenotype associated with a 39-CAG-repeat expansion in ATXN7. This patient had neither ataxia nor retinal dystrophy, but she had an oculomotor cerebellar syndrome and a family history suggestive of SCA7. In SCA7, shorter expansions may be associated with less severe and incomplete clinical phenotypes, which could explain the patient's phenotype. Unknown genetic and environmental factors may also influence the patient's phenotype. We suggest that a pathological expansion in ATXN7 should be considered in cases of ALS-like phenotype, particularly when associated with oculomotor abnormalities or a family history of ataxia or blindness.
Collapse
Affiliation(s)
- Florent Cluse
- ALS Resource and Competence Centre, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.,Electroneuromyography and Neuromuscular Diseases Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France
| | - Emilien Bernard
- ALS Resource and Competence Centre, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.,Electroneuromyography and Neuromuscular Diseases Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.,NeuroMyoGène Institute, CNRS UMR5310, INSERM U1217, University of Lyon I, Lyon, France
| | | | - David Devos
- Department of Pharmacology, LiCEND, ALS Expert Center, University Hospital of Lille, University of Lille, Lille Neuroscience & Cognition, Inserm U1172, Lille, France
| | - Kevin Mouzat
- Laboratory of Biochemistry and Molecular Biology, University Hospital of Nîmes, Nîmes, Motoneuron Disease: Pathophysiology and Therapy, INM, University of Montpellier, Montpellier, France
| | - Serge Lumbroso
- Laboratory of Biochemistry and Molecular Biology, University Hospital of Nîmes, Nîmes, Motoneuron Disease: Pathophysiology and Therapy, INM, University of Montpellier, Montpellier, France
| | - Caroline Froment Tilikete
- Neuro-ophtalmology and Neuro-cognition Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.,Faculté de médecine Lyon Est, University of Lyon, Lyon, France.,Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR 5292, Team impact, Bron, France
| | - StÉphane Thobois
- ALS Resource and Competence Centre, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.,Faculté de médecine et de Maïeutique Lyon Sud Charles Mérieux, University of Lyon, Lyon, France, and.,CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229, Bron, France
| | - Antoine Pegat
- ALS Resource and Competence Centre, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.,Electroneuromyography and Neuromuscular Diseases Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France
| |
Collapse
|
2
|
Bouzid FZ, Mansouri M, Abdelaziz C, Louhab N, Bernard S, Strubi-Vuillaume I, Dafir K, Aboussair N. Spinocerebellar ataxia Type 7: clinical and genetic study of a new Moroccan family (case report). Pan Afr Med J 2021; 38:162. [PMID: 33995769 PMCID: PMC8077635 DOI: 10.11604/pamj.2021.38.162.27262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 01/07/2021] [Indexed: 11/11/2022] Open
Abstract
Spinocerebellar ataxia type 7 (SCA7) is a rare autosomal dominant neurodegenerative disease. Its clinical presentation is a progressive cerebellar ataxia associated with cone and retinal dystrophy. The CAG repeat expansion in the ataxin-7 gene (ATXN7) causes spinocerebellar ataxia type 7 - a mutation that results in the degeneration of the brain stem cells, retina and cerebellum. We report in this study the clinical and genetic features of a new Moroccan family of SCA7, from the South of Morocco. We performed the molecular genetic testing to confirm the diagnosis of SCA7. The objective of this study is to report a new Moroccan case of SCA7 and to illustrate the role of the geneticist in the diagnosis, management and development of genetic counseling of SCA7 disease.
Collapse
Affiliation(s)
- Fatima Zahra Bouzid
- Genetics Department, Clinical Research Center, University Hospital Centre Mohammed VI, Marrakech, Morocco.,School of Medicine and Pharmacy of Marrakech, Cadi Ayyad University, Marrakech, Morocco
| | - Maria Mansouri
- Genetics Department, Clinical Research Center, University Hospital Centre Mohammed VI, Marrakech, Morocco
| | | | - Nisrine Louhab
- School of Medicine and Pharmacy of Marrakech, Cadi Ayyad University, Marrakech, Morocco.,Neurology Department, University Hospital Centre Mohammed VI, Marrakech, Morocco
| | - Sablonniere Bernard
- Biochemistry and Molecular Biology Pole, Department of Neurobiology Biology Pathology Center, Lille University Hospital, Lille, French
| | | | - Kenza Dafir
- Genetics Department, Clinical Research Center, University Hospital Centre Mohammed VI, Marrakech, Morocco.,School of Medicine and Pharmacy of Marrakech, Cadi Ayyad University, Marrakech, Morocco
| | - Nisrine Aboussair
- Genetics Department, Clinical Research Center, University Hospital Centre Mohammed VI, Marrakech, Morocco.,School of Medicine and Pharmacy of Marrakech, Cadi Ayyad University, Marrakech, Morocco
| |
Collapse
|
3
|
Aerts C, Cassim F, Strubi-Vuillaume I, Destée A, Sablonnière B, Collod-Béroud G, Defebvre L, Kreisler A. Writing tremor: Should we look for a TOR1A mutation? J Neurol Sci 2017; 382:146-147. [DOI: 10.1016/j.jns.2017.09.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Revised: 08/30/2017] [Accepted: 09/28/2017] [Indexed: 10/18/2022]
|
4
|
Huin V, Strubi-Vuillaume I, Dujardin K, Brion M, Delliaux M, Dellacherie D, Cuvellier JC, Cuisset JM, Riquet A, Moreau C, Defebvre L, Sablonnière B, Devos D. Expanding the phenotype of SCA19/22: Parkinsonism, cognitive impairment and epilepsy. Parkinsonism Relat Disord 2017; 45:85-89. [PMID: 28947073 DOI: 10.1016/j.parkreldis.2017.09.014] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Revised: 09/01/2017] [Accepted: 09/13/2017] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Spinocerebellar ataxia types 19 and 22 (SCA19/22) are rare conditions in which relatively isolated cerebellar involvement is frequently associated with cognitive impairment. Here, we report on new clinical features and provide details of the cognitive profile in two SCA19/22 families. METHODS Two families displaying an autosomal-dominant form of cerebellar ataxia underwent clinical examinations and genetic testing. RESULTS In addition to the classical clinical features of SCA, a wide spectrum of cognitive disorders (including visuospatial impairments) was observed. Eight patients had mild Parkinsonism, and five had epilepsy. Genetic testing showed that the KCND3 mutation (c.679_681delTTC, p.F227del) was present in both families. CONCLUSIONS Our findings broaden the phenotypic spectrum of SCA19/22, and suggest that KCND3 should be included in the list of candidate genes for epilepsy, Parkinsonism and cognitive impairment.
Collapse
Affiliation(s)
- Vincent Huin
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France; CHU Lille, Institut de Biochimie et Biologie moléculaire, Centre de Biologie Pathologie et Génétique, F-59000, Lille, France.
| | - Isabelle Strubi-Vuillaume
- CHU Lille, Institut de Biochimie et Biologie moléculaire, Centre de Biologie Pathologie et Génétique, F-59000, Lille, France
| | - Kathy Dujardin
- Univ. Lille, Inserm, CHU Lille, U1171 - Degenerative & vascular cognitive disorders, F-59000, Lille, France; CHU Lille, Service de Neurologie et Pathologies du Mouvement, Hôpital Roger Salengro, F-59000, Lille, France
| | - Marine Brion
- CHU Lille, Service de Neurologie et Pathologies du Mouvement, Hôpital Roger Salengro, F-59000, Lille, France
| | - Marie Delliaux
- CHU Lille, Service de Neurologie et Pathologies du Mouvement, Hôpital Roger Salengro, F-59000, Lille, France
| | - Delphine Dellacherie
- CHU Lille, Service de Neuropédiatrie, Hôpital Roger Salengro, F-59000, Lille, France
| | | | - Jean-Marie Cuisset
- CHU Lille, Service de Neuropédiatrie, Hôpital Roger Salengro, F-59000, Lille, France
| | - Audrey Riquet
- CHU Lille, Service de Neuropédiatrie, Hôpital Roger Salengro, F-59000, Lille, France
| | - Caroline Moreau
- Univ. Lille, Inserm, CHU Lille, U1171 - Degenerative & vascular cognitive disorders, F-59000, Lille, France; CHU Lille, Service de Neurologie et Pathologies du Mouvement, Hôpital Roger Salengro, F-59000, Lille, France
| | - Luc Defebvre
- Univ. Lille, Inserm, CHU Lille, U1171 - Degenerative & vascular cognitive disorders, F-59000, Lille, France; CHU Lille, Service de Neurologie et Pathologies du Mouvement, Hôpital Roger Salengro, F-59000, Lille, France
| | - Bernard Sablonnière
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France; CHU Lille, Institut de Biochimie et Biologie moléculaire, Centre de Biologie Pathologie et Génétique, F-59000, Lille, France
| | - David Devos
- Univ. Lille, Inserm, CHU Lille, U1171 - Degenerative & vascular cognitive disorders, F-59000, Lille, France; CHU Lille, Service de Neurologie et Pathologies du Mouvement, Hôpital Roger Salengro, F-59000, Lille, France; CHU Lille, Service de Pharmacologie médicale, Faculté de Médecine, F-59045, Lille, France
| |
Collapse
|
5
|
Strubi-Vuillaume I, Carlier V, Obeuf C, Vasseur F, Maury JC, Maboudou P, Mangalaboyi J, Durocher A, Launay D, Noel C, Brousseau T. Gentle blood aspiration and tube cushioning reduce pneumatic tube system interference in lactate dehydrogenase assays. Ann Clin Biochem 2015; 53:295-7. [DOI: 10.1177/0004563215586600] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/21/2015] [Indexed: 11/16/2022]
Abstract
Background Use of a hospital pneumatic tube system may be associated with measurement errors. Methods A venous blood sample was collected from 79 patients into a pair of lithium heparin tubes; one tube was sent to the laboratory by porter and the other was sent via the pneumatic tube system. Plasma lactate dehydrogenase concentrations were then assayed. Results Lactate dehydrogenase concentrations were overestimated (median bias: 18.8%) when evacuated vacuum lithium heparin tubes were sent by pneumatic tube system. This bias was reduced by bubble-wrapping the standard lithium heparin tube or using Monovette lithium heparin tubes in aspiration mode (median bias: +8.7% and −0.3%, respectively). Conclusions Cushioning and aspiration-mode sampling may limit pneumatic tube system-associated overestimation of lactate dehydrogenase concentrations.
Collapse
Affiliation(s)
- Isabelle Strubi-Vuillaume
- UF 8832 – Biochimie Automatisée, Pôle de Biologie Pathologie Génétique, CHRU de Lille, Lille, France
| | - Valentine Carlier
- UF 8832 – Biochimie Automatisée, Pôle de Biologie Pathologie Génétique, CHRU de Lille, Lille, France
| | - Catherine Obeuf
- UF 8832 – Biochimie Automatisée, Pôle de Biologie Pathologie Génétique, CHRU de Lille, Lille, France
| | - Francis Vasseur
- EA 2694, Unité de Biostatistique, Université Lille Nord de France, Lille, France
| | - J-Claude Maury
- UF 8832 – Biochimie Automatisée, Pôle de Biologie Pathologie Génétique, CHRU de Lille, Lille, France
| | - Patrice Maboudou
- UF 8832 – Biochimie Automatisée, Pôle de Biologie Pathologie Génétique, CHRU de Lille, Lille, France
| | - Jacques Mangalaboyi
- Service de Réanimation, Hôpital Roger Salengro, CHRU de Lille, Lille, France
| | - Alain Durocher
- Service de Réanimation, Hôpital Calmette, CHRU de Lille, Lille, France
| | - David Launay
- Service de Médecine Interne, Hôpital Huriez, CHRU de Lille, Lille, France
| | - Christian Noel
- Service de Néphrologie, Hôpital Huriez, CHRU de Lille, Lille, France
| | - Thierry Brousseau
- UF 8832 – Biochimie Automatisée, Pôle de Biologie Pathologie Génétique, CHRU de Lille, Lille, France
| |
Collapse
|
6
|
Delplanque J, Devos D, Huin V, Genet A, Sand O, Moreau C, Goizet C, Charles P, Anheim M, Monin ML, Buée L, Destée A, Grolez G, Delmaire C, Dujardin K, Dellacherie D, Brice A, Stevanin G, Strubi-Vuillaume I, Dürr A, Sablonnière B. TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment. Brain 2014; 137:2657-63. [DOI: 10.1093/brain/awu202] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014; 21:195-210. [PMID: 24251381 PMCID: PMC4060813 DOI: 10.1089/ars.2013.5593] [Citation(s) in RCA: 427] [Impact Index Per Article: 42.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
AIMS The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Translational cell and animal models provided concept proofs and a delayed-start (DS) treatment paradigm, the basis for preliminary clinical assessments. RESULTS For translational studies, we assessed the effect of oxidative insults in mice systemically prechelated with deferiprone (DFP) by following motor functions, striatal dopamine (HPLC and MRI-PET), and brain iron deposition (relaxation-R2*-MRI) aided by spectroscopic measurements of neuronal labile iron (with fluorescence-sensitive iron sensors) and oxidative damage by markers of protein, lipid, and DNA modification. DFP significantly reduced labile iron and biological damage in oxidation-stressed cells and animals, improving motor functions while raising striatal dopamine. For a pilot, double-blind, placebo-controlled randomized clinical trial, early-stage Parkinson's patients on stabilized dopamine regimens enrolled in a 12-month single-center study with DFP (30 mg/kg/day). Based on a 6-month DS paradigm, early-start patients (n=19) compared to DS patients (n=18) (37/40 completed) responded significantly earlier and sustainably to treatment in both substantia nigra iron deposits (R2* MRI) and Unified Parkinson's Disease Rating Scale motor indicators of disease progression (p<0.03 and p<0.04, respectively). Apart from three rapidly resolved neutropenia cases, safety was maintained throughout the trial. INNOVATION A moderate iron chelation regimen that avoids changes in systemic iron levels may constitute a novel therapeutic modality for PD. CONCLUSIONS The therapeutic features of a chelation modality established in translational models and in pilot clinical trials warrant comprehensive evaluation of symptomatic and/or disease-modifying potential of chelation in PD.
Collapse
Affiliation(s)
- David Devos
- 1 Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University , CHU Lille, Lille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|